Unlocking the Potential of Ribosomal Protein Lateral Stalk Subunit P1 Pseudogene 7 as a Drug Target or Biomarker

Target Name: RPLP1P7

NCBI ID: G133609

RPLP1P7

Other Name(s): ribosomal protein lateral stalk subunit P1 pseudogene 7 | Ribosomal protein, large, P1 pseudogene 7 | RPLP1_4_611

Unlocking the Potential of Ribosomal Protein Lateral Stalk Subunit P1 Pseudogene 7 as a Drug Target or Biomarker

Introduction

The Ribosomal protein (RP) family is the largest protein family in cells and is responsible for the synthesis of rRNA in ribosomes. The RP family includes multiple functional subtypes, among which RP1P7 is an interesting gene located on human chromosome 1p36.1. The protein encoded by the RP1P7 gene is a non-ribosomal RNA (hnRNA) that is transcribed in the nucleus and transported to ribosomes in the cytoplasm for translation. Variation and dysfunction of the RP1P7 gene are closely related to a variety of diseases, such as cancer, neurodegenerative diseases, and immune disorders.

In recent years, with the development of high-throughput sequencing technology, researchers have conducted in-depth studies on the function of the RP1P7 gene. Many studies have found that variations in the RP1P7 gene are closely related to the occurrence and development of various diseases. In addition, the expression level of RP1P7 gene is closely related to the progression and treatment response of various tumors. These findings have brought great attention to the therapeutic potential of the RP1P7 gene.

Structure and function of the RP1P7 gene

The protein encoded by the RP1P7 gene is a 28kDa ribosomal RNA (rRNA), mainly composed of two subunits: P1 and P2. The P1 subunit includes an open reading frame (ORF) and an N-terminal tail, while the P2 subunit includes a conserved 伪-helix and a C-terminal tail. The P1 and P2 subunits interact through hydrogen bonds and van der Waals forces to form dimers, which is the main mechanism for RP1P7 gene stability.

Variations in the RP1P7 gene

Variations in the RP1P7 gene mainly occur in the ORF region. Studies have found that variations in the RP1P7 gene are closely related to the occurrence and development of a variety of diseases, such as neurodegenerative diseases, cancer, and immune disorders. These mutations lead to changes in the expression levels of the RP1P7 gene, thereby affecting cellular metabolism and biological processes.

The relationship between RP1P7 gene and diseases

Many studies have found that variations in the RP1P7 gene are closely related to the occurrence and development of various diseases. For example, studies have found that variations in the RP1P7 gene are closely related to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as immune disorders, such as autoimmune diseases and rejection after organ transplantation. In addition, the expression level of RP1P7 gene is closely related to the progression and treatment response of various tumors.

Therapeutic potential of the RP1P7 gene

Because variations in the RP1P7 gene are closely related to the occurrence and development of various diseases, it is considered a potential drug target or biomarker. In recent years, researchers have conducted extensive research on the therapeutic potential of the RP1P7 gene.

Drug screening of RP1P7 gene

To screen drug targets for the RP1P7 gene, researchers used a variety of screening methods. First, RP1P7 gene knockout mice were used to screen drug targets of the RP1P7 gene. Secondly, RP1P7 gene overexpression mice were used to screen drug targets of the RP1P7 gene. Finally, variants of the RP1P7 gene were used to screen drug targets of the RP1P7 gene. These studies have brought great attention to the therapeutic potential of the RP1P7 gene.

Biomarker research on RP1P7 gene

Biomarker research on the RP1P7 gene is an important component of RP1P7 gene therapy. Many studies have found that variations in the RP1P7 gene are closely related to the occurrence and development of various diseases, such as neurodegenerative diseases, cancer, and immune disorders. These mutations lead to changes in the expression levels of the RP1P7 gene, thereby affecting cellular metabolism and biological processes.

Clinical application of RP1P7 gene

Because variations in the RP1P7 gene are closely related to the occurrence and development of various diseases, it is considered a potential drug target or biomarker. In recent years, researchers have conducted extensive studies on the clinical application of the RP1P7 gene.

RP1P7 gene therapy

RP1P7 gene therapy is a treatment method that uses the RP1P7 gene as a drug target or biomarker. In recent years, researchers have conducted extensive research on RP1P7 gene therapy. For example, researchers have found that the RP1P7 gene may serve as a treatment for neurodegenerative diseases such as

Protein Name: Ribosomal Protein Lateral Stalk Subunit P1 Pseudogene 7

The "RPLP1P7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPLP1P7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets